Updated results of the phase 3 AXIS trial: Axitinib vs sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC)

被引：0
|
作者：
Escudier, B. [1 ]
Rini, B., I [2 ]
Hutson, T. E. [3 ]
Gore, M. [4 ]
Oudard, S. [5 ]
Tarazi, J. [6 ]
Rosbrook, B. [6 ]
Williams, J. A. [7 ]
Kim, S. [6 ]
Motzer, R. J. [8 ]
机构：
[1] Inst Gustave Roussy, Dept Med Oncol, Villejuif, France
[2] Cleveland Clin, Taussig Canc Inst, Dept Solid Tumor Oncol, Cleveland, OH 44106 USA
[3] Baylor Sammons Texas Oncol Phys Assoc, Dept Oncol, Dallas, TX USA
[4] Royal Marsden Hosp, Dept Med, London SW3 6JJ, England
[5] Georges Pompidou European Hosp, Dept Med Oncol, Paris, France
[6] Pfizer Oncol, Dept Clin Oncol, San Diego, CA USA
[7] Pfizer Oncol, Dept Translat Oncol, San Diego, CA USA
[8] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
来源：
EUROPEAN UROLOGY SUPPLEMENTS | 2012年 / 11卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E81 / U450
页数：2
相关论文
共 50 条
  • [21] Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial (vol 14, pg 552, 2013)
    Motzer, R. J.
    Escudier, B.
    Tomczak, P.
    LANCET ONCOLOGY, 2013, 14 (07): : E254 - E254
  • [22] Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma
    Hutson, Thomas E.
    Escudier, Bernard
    Esteban, Emilio
    Bjarnason, Georg A.
    Lim, Ho Yeong
    Pittman, Kenneth B.
    Senico, Peggy
    Niethammer, Andreas
    Lu, Dongrui Ray
    Hariharan, Subramanian
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (08) : 760 - +
  • [23] A Prospectivly Randomized Phase-II Trial of Axitinib versus Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma (BERAT Study)
    Gruenwald, Viktor
    Hilser, Thomas
    Meiler, Johannes
    Goebell, Peter J.
    Ivanyi, Philipp
    Strauss, Arne
    Hartmann, Arndt
    Bedke, Jens
    Bergmann, Lothar
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (05) : 272 - 280
  • [24] New prognostic factors for second-line targeted therapy (TT) in metastatic renal cell carcinoma (mRCC)
    Derosa, L.
    Guida, A.
    Albiges, L.
    Massard, C.
    Loriot, Y.
    Biasco, E.
    Farnesi, A.
    Marconcini, R.
    Galli, L.
    Falcone, A.
    Fizazi, K.
    Escudier, B.
    ANNALS OF ONCOLOGY, 2015, 26 : 53 - 53
  • [25] New prognostic factors for second-line targeted therapy (TT) in metastatic renal cell carcinoma (mRCC)
    Derosa, L.
    Guida, A.
    Albiges, L.
    Massard, C.
    Loriot, Y.
    Galli, L.
    Fizazi, K.
    Escudier, B.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S478 - S479
  • [26] Efficacy of Axitinib as Second-line Treatment in Locally Advanced and Metastatic Renal Cell Carcinoma
    Ueda, Kosuke
    Suekane, Shigetaka
    Hirano, Taishi
    Ogasawara, Naoyuki
    Chikui, Katsuaki
    Uemura, Keiichiro
    Nakiri, Makoto
    Nishihara, Kiyoaki
    Matsuo, Mitsunori
    Igawa, Tsukasa
    ANTICANCER RESEARCH, 2018, 38 (09) : 5387 - 5392
  • [27] Updated results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC)
    Sosman, J. A.
    Flaherty, K. T.
    Atkins, M. B.
    McDermott, D. F.
    Rothenberg, M. L.
    Vermeulen, W. L.
    Harlacker, K.
    Hsu, A.
    Wright, J. J.
    Puzanov, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [28] Overall survival analysis from a randomised phase III trial of axitinib vs sorafenib as first-line therapy in patients with metastatic renal cell carcinoma
    Hutson, T. E.
    Al-Shukri, S.
    Stus, V. P.
    Lipatov, O. N.
    Shparyk, Y.
    Bair, A. H.
    Rosbrook, B.
    Andrews, G. I.
    Vogelzang, N. J.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S476 - S477
  • [29] First-line axitinib versus sorafenib in Asian patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis of data from a phase III trial
    Sheng, X.
    Bi, F.
    Ren, X.
    Cheng, Y.
    Wang, J.
    Rosbrook, B.
    Jiang, M.
    Guo, J.
    ANNALS OF ONCOLOGY, 2017, 28 : 82 - 82
  • [30] PHASE III AXIS TRIAL OF AXITINIB VERSUS SORAFENIB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA: ASIAN SUBGROUP ANALYSIS
    Uemura, H.
    Ou, Y. -C.
    Lim, H. Y.
    Tomita, Y.
    Ueda, T.
    Menon, H.
    Chung, J.
    Guo, J.
    Tarazi, J.
    Kim, S.
    Naito, S.
    Akaza, H.
    ANNALS OF ONCOLOGY, 2012, 23 : 6 - 6
12345